• Home
  1. Home
  2. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
Scientific article
OA Policy
English

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries

ContributorsLauper, Kimorcid; Mongin, Denisorcid; Iannone, Florenzo; Klami Kristianslund, Eirik; Kvien, Tore K; Nordström, Dan; Pavelka, Karel; Pombo-Suarez, Manuel; Rotar, Ziga; Santos, Maria Jose; Codreanu, Catalin; Lukina, Galina; Courvoisier, Delphineorcid; Gabay, Cem
Published inRMD Open, vol. 4, no. 2, e000809
Publication date2018
Abstract

To compare the real-word effectiveness of subcutaneous tocilizumab (TCZ-SC) and intravenous tocilizumab (TCZ-IV) in rheumatoid arthritis (RA).

Keywords
  • DMARDs
  • Biological therapies
  • Epidemiology
  • Intravenous
  • Rheumatoid arthritis
  • Subcutaneous
  • Tocilizumab
Affiliation entities
Research groups
Citation (ISO format)
LAUPER, Kim et al. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. In: RMD Open, 2018, vol. 4, n° 2, p. e000809. doi: 10.1136/rmdopen-2018-000809
Main files (1)
Article (Published version)
accessLevelPublic CC BY-NC
Identifiers
Additional URL for this publicationhttps://rmdopen.bmj.com/content/4/2/e000809
Journal ISSN2056-5933
352views
164downloads

Technical informations

Creation05/12/2019 11:17:00
First validation05/12/2019 11:17:00
Update time03/02/2025 12:56:32
Status update03/02/2025 12:56:32
Last indexation03/02/2025 13:01:42
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack